Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study

Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study

<p><strong>Background</strong> Dolutegravir (DTG) is recommended for second-line antiretroviral therapy (ART) after virological failure on first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens in people living with HIV in low-income and middle-income coun...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Asare, K, Sookrajh, Y, van der Molen, J, Khubone, T, Lewis, L, Lessells, RJ, Naidoo, K, Sosibo, P, van Heerden, R, Garrett, N, Dorward, J
Format:	Journal article
Język:	English
Wydane:	Elsevier 2023

Podobne zapisy

Clinical outcomes after Viremia among people receiving dolutegravir vs efavirenz-based first-line antiretroviral therapy in South Africa
od: Asare, K, i wsp.
Wydane: (2023)

Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study
od: Dorward, J, i wsp.
Wydane: (2023)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen
od: Keene, CM, i wsp.
Wydane: (2021)

Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research
od: Dorward, J, i wsp.
Wydane: (2018)

Clinical outcomes after extended 12-month antiretroviral therapy prescriptions in a community-based differentiated HIV service delivery programme in South Africa: a retrospective cohort study
od: Lewis, L, i wsp.
Wydane: (2023)

Clinical outcomes after extended 12-month antiretroviral therapy prescriptions in a community-based differentiated HIV service delivery programme in South Africa: a retrospective cohort study
od: Lewis, L, i wsp.
Wydane: (2023)

Viremia and HIV drug resistance among people receiving dolutegravir versus efavirenz-based first-line antiretroviral therapy
od: Dorward, J, i wsp.
Wydane: (2024)

Long‐term usage patterns and clinical outcomes in a community‐based differentiated antiretroviral therapy delivery programme in South Africa
od: Lewis, L, i wsp.
Wydane: (2023)

Differentiated service delivery for people using second-line antiretroviral therapy: clinical outcomes from a retrospective cohort study in KwaZulu-Natal, South Africa
od: Lewis, L, i wsp.
Wydane: (2021)

Point-of-care viral load testing to manage HIV viraemia during the rollout of dolutegravir-based ART in South Africa: a randomised feasibility study (POwER)
od: Dorward, J, i wsp.
Wydane: (2023)

Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir based antiretroviral therapy
od: Dorward, J, i wsp.
Wydane: (2023)

Dolutegravir in sub-Saharan Africa: context is crucial
od: Dorward, J, i wsp.
Wydane: (2018)

Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.
od: DART Virology Group and Trial Team
Wydane: (2006)

Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy
od: Dorward, J, i wsp.
Wydane: (2023)

Does tenofovir-containing first-line antiretroviral therapy mitigate the impact of pretreatment non-nucleoside reverse transcriptase inhibitor drug resistance?
od: Inzaule, SC, i wsp.
Wydane: (2018)

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration
od: Rhee, S, i wsp.
Wydane: (2017)

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.
od: Esnouf, R, i wsp.
Wydane: (1995)

Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks
od: Keene, CM, i wsp.
Wydane: (2023)

HEPT: From an investigation of lithiation of nucleosides towards a rational design of non-nucleoside reverse transcriptase inhibitors of HIV-1
od: Tanaka, H, i wsp.
Wydane: (1999)

HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in sub-Saharan Africa
od: Kityo, C, i wsp.
Wydane: (2017)

Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens
od: Inzaule, SC, i wsp.
Wydane: (2019)

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
od: Ren, J, i wsp.
Wydane: (2008)

2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
od: Chan, J, i wsp.
Wydane: (2001)

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
od: Paton, N, i wsp.
Wydane: (2017)

HIV treatment outcomes among people with initiation CD4 counts >500 cells/µL after implementation of Treat All in South African public clinics: a retrospective cohort study
od: Dorward, J, i wsp.
Wydane: (2020)

Initial supplementary dose of dolutegravir in second-line antiretroviral therapy: a noncomparative, double-blind, randomized placebo-controlled trial
od: Zhao, Y, i wsp.
Wydane: (2023)

Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial
od: Aboulker, J, i wsp.
Wydane: (2002)

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
od: Paton, N, i wsp.
Wydane: (2014)

Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2.
od: Milton, J, i wsp.
Wydane: (1998)

Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase.
od: Pelemans, H, i wsp.
Wydane: (1998)

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial
od: Zhao, Y, i wsp.
Wydane: (2021)

Mechanisms of nucleoside analogue resistance associated with the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms
od: Betancor, G, i wsp.
Wydane: (2010)

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
od: Hopkins, A, i wsp.
Wydane: (2004)

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
od: Freeman, G, i wsp.
Wydane: (2004)

Assessment of second-line antiretroviral regimens for HIV therapy in Africa
od: Paton, N, i wsp.
Wydane: (2014)

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
od: Hakim, J, i wsp.
Wydane: (2017)

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
od: Hakim, J, i wsp.
Wydane: (2017)

Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses.
od: Ren, J, i wsp.
Wydane: (2000)

Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.
od: Ren, J, i wsp.
Wydane: (2002)

Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies.
od: Ren, J, i wsp.
Wydane: (1999)